Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Medical Oncology
• Biostatistics

Background:

• Paclitaxel is a vital chemotherapy agent used in various cancers.
• Optimal dosing and administration schedules are crucial for maximizing efficacy and minimizing toxicity.
• Previous studies have suggested varying outcomes based on paclitaxel dose and regimen.

Purpose of the Study:

• To quantify the effects of paclitaxel dose and administration schedule (weekly vs. every 3 weeks) on treatment efficacy and safety.
• To guide optimal dose and regimen selection for paclitaxel therapy in cancer patients.
• To establish dose-response relationships for paclitaxel efficacy and safety outcomes.

Main Methods:

• A model-based meta-analysis was conducted on data from 29 paclitaxel monotherapy trials.
• Logistic regression models were used to assess the relationship between dose and objective response or neutropenia rates.
• Survival models were employed to evaluate the impact of dose on overall survival and progression-free survival.

Main Results:

• Paclitaxel efficacy, including objective response rate and survival metrics, was correlated with the average weekly dose (mg/m(2)/week).
• Paclitaxel safety, specifically neutropenia incidence, was correlated with the dose administered per administration (mg/m(2)).
• A weekly regimen of 65-80 mg/m(2) demonstrated comparable or superior efficacy with a lower incidence of neutropenia compared to an every-3-week regimen of 175 mg/m(2).

Conclusions:

• The findings support a weekly paclitaxel regimen at 65-80 mg/m(2) as a potentially more effective and safer option than the standard every-3-week regimen.
• Dose per week and dose per administration are critical determinants of paclitaxel's efficacy and safety profile, respectively.
• Model-based meta-analysis provides a robust framework for optimizing chemotherapy dosing strategies.